A significant negative association was found between aerobic exercise intensity and fatigue reduction .
A peak effect was found for moderate-intensity aerobic exercise for improving walking endurance .
No dose-response relationship was found between exercise and markers of inflammation or exercise duration and outcomes .
Rates of adherence were typically high and few adverse events were reported .
Exercise is safe , reduces fatigue and increases endurance in cancer survivors .
QUESTION Is there a dose-response effect of exercise on inflammation , fatigue and activity in cancer survivors ?
Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial.
BACKGROUND Exercise improves physical functioning and symptom management during breast cancer chemotherapy , but the effects of different doses and types of exercise are unknown . METHODS A multicenter trial in Canada r and omized 301 breast cancer patients to thrice-weekly supervised exercise during chemotherapy  consisting of either a st and ard dose of 25 to 30 minutes of aerobic exercise ( STAN ; n = 96 ) , a higher dose of 50 to 60 minutes of aerobic exercise ( HIGH ; n = 101 ) , or a combined dose of 50 to 60 minutes of aerobic and resistance exercise ( COMB ; n = 104 ) . The primary endpoint was physical functioning assessed by the Medical Outcomes Survey-Short Form (SF)-36 . Secondary endpoints were other physical functioning scales , symptoms , fitness , and chemotherapy completion . All statistical tests were linear mixed model analyses , and the P values were two-sided . RESULTS Follow-up assessment of patient-reported outcomes was 99.0 % . Adjusted linear mixed-model analyses showed that neither HIGH ( + 0.8 ; 95 % confidence interval [ CI ] = -0.8 to 2.4 ; P = .30 ) nor COMB ( + 0.5 ; 95 % CI = -1.1 to 2.1 ; P = .52 ] were superior to STAN for the primary outcome . In secondary analyses not adjusted for multiple comparisons , HIGH was superior to STAN for the SF-36 physical component summary ( P = .04 ) , SF-36 bodily pain ( P = .02 ) , and endocrine symptoms ( P = .02 ) . COMB was superior to STAN for endocrine symptoms ( P = .009 ) and superior to STAN ( P < .001 ) and HIGH ( P < .001 ) for muscular strength . HIGH was superior to COMB for the SF-36 bodily pain ( P = .04 ) and aerobic fitness ( P = .03 ) . No differences emerged for body composition or chemotherapy completion . CONCLUSIONS A higher volume of aerobic or combined exercise is achievable and safe during breast cancer chemotherapy and may manage declines in physical functioning and worsening symptoms better than st and ard volumes
A significant negative association was found between aerobic exercise intensity and fatigue reduction .
A peak effect was found for moderate-intensity aerobic exercise for improving walking endurance .
No dose-response relationship was found between exercise and markers of inflammation or exercise duration and outcomes .
Rates of adherence were typically high and few adverse events were reported .
Exercise is safe , reduces fatigue and increases endurance in cancer survivors .
QUESTION Is there a dose-response effect of exercise on inflammation , fatigue and activity in cancer survivors ?